SCHEMBL3822896

SCHEMBL3822896

O=C(ON1CCOCC1)C(=O)ON1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MMP1 P03956 1/20 0.38
MMP3 P08254 1/20 0.38
MMP8 P22894 1/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29200488 0.90 HSD17B10 (0.40) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL4018378 0.84 L3MBTL1 (0.41) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL538784 0.84 TSHR (0.55) L3MBTL1SMN1; SMN2KMT2ATSHRRECQL
SCHEMBL2960232 0.83 SMN1; SMN2 (0.42) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL1371997 0.83 SMN1; SMN2 (0.42) L3MBTL1SMN1; SMN2CA12CA1CA9
Ammonia Solution, Strong SCHEMBL9998480 0.82 L3MBTL1 (0.40) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL4695520 0.82 HSD17B10 (0.41) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL3335816 0.81 SMN1; SMN2 (0.41) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL17530343 0.80 TSHR (0.41) L3MBTL1SMN1; SMN2CA12CA1CA9
SCHEMBL249323 0.80 SMN1; SMN2 (0.48) L3MBTL1SMN1; SMN2CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110437069-A The method for continuously synthesizing of 2- fluorine diester malonate class compound ASYMCHEM LIFE SCIENCE TIANJIN CO LTD 2019-11-12 CN claimed
CN-101595098-B 1,2,4-triazole derivatives as sigma receptor inhibitors ESTEVE LABOR DR 2012-07-18 CN claimed
CN-101595098-A As 1,2 of sigma receptor inhibitors, the 4-triazole derivative ESTEVE LABOR DR (ES) 2009-12-02 CN claimed
EP-2097394-A1 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-09-09 EP claimed
WO-2008055932-A1 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-05-15 WO claimed
CN-119768395-A Processes and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives 库里亚西班牙公司 2025-04-04 CN disclosed
US-20200179254-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2020-06-11 US disclosed
CN-110437069-A The method for continuously synthesizing of 2- fluorine diester malonate class compound ASYMCHEM LIFE SCIENCE TIANJIN CO LTD 2019-11-12 CN disclosed
US-20190240129-A1 CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-08-08 US disclosed
EP-3518878-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION Henkel AG & Co. KGaA (DE) 2019-08-07 EP disclosed
US-20190216703-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-07-18 US disclosed
US-20190216714-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-07-18 US disclosed
CN-102036985-A 4(-3- (-2- (phenyl) morpholino) -2-oxopyrrolidin-1-yl) -N- (thiazol-2-yl) benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain VERTEX PHARMA 2011-04-27 CN disclosed
CN-101595098-A As 1,2 of sigma receptor inhibitors, the 4-triazole derivative ESTEVE LABOR DR (ES) 2009-12-02 CN disclosed
EP-2097394-A1 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-09-09 EP disclosed
CN-101395152-A Sigma receptor compounds ESTEVE LABOR DR (ES) 2009-03-25 CN disclosed
WO-2008055932-A1 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-05-15 WO disclosed
CN-101014570-A Piperidine derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2007-08-08 CN disclosed
CN-1021323-C PROCESS FOR PREPARING ANTIDEPRESSANTS MERRELL DOW PHARMA (US) 1993-06-23 CN disclosed
CN-1033043-A The method for making of new antidepressive MERRELL DOW PHARMA (US) 1989-05-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240129-A1 CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CUTA, S100A10 L3MBTL1 4779/4885SMN1; SMN2 3900/4885CA12 194/4885
US-20190216703-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, SRRM2, IK L3MBTL1 4634/4885SMN1; SMN2 4150/4885CA12 564/4885
US-20190216714-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CD44, PCNA L3MBTL1 4760/4885SMN1; SMN2 2681/4885CA12 188/4885
US-20200179254-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CUTA, DSG1 L3MBTL1 4594/4885SMN1; SMN2 3725/4885CA12 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.